BRAF inhibitors in Melanoma: Structural Insights, Therapeutic Resistance, and Biological Evaluation of Quinazoline Derivatives
Arghya Paik(Drug Discovery Laboratory (Norway)), Hemalatha Kamurthy(Drug Discovery Laboratory (Norway)), Rohit Pal(Unknown), Abhishek Ghara(Unknown), Gurubasavaraja Swamy Purawarga Matada(Drug Discovery Laboratory (Norway))
Cited by 8
Related Papers
Molecular docking and molecular dynamic studies: screening of phytochemicals against EGFR, HER2, estrogen and NF-KB receptors for their potential use in breast cancer
|Journal of Biomolecular Structure and Dynamics|2021|37
DDR1 and DDR2: a review on signaling pathway and small molecule inhibitors as an anticancer agent
|Medicinal Chemistry Research|2021|35
Benzothiazole a privileged scaffold for Cutting-Edges anticancer agents: Exploring drug design, structure-activity relationship, and docking studies
|European Journal of Medicinal Chemistry|2024|32
An assessment of EGFR and HER2 inhibitors with structure activity relationship of fused pyrimidine derivatives for breast cancer: a brief review
|Journal of Biomolecular Structure and Dynamics|2023|28
An updated literature on BRAF inhibitors (2018–2023)
|Molecular Diversity|2023|24